A phase I/II study to evaluate the efficacy and toxicity of imatinib mesylate in combination with dacarbazine and capecitabine in medullary thyroid carcinoma.

Trial Profile

A phase I/II study to evaluate the efficacy and toxicity of imatinib mesylate in combination with dacarbazine and capecitabine in medullary thyroid carcinoma.

Discontinued
Phase of Trial: Phase I/II

Latest Information Update: 22 Dec 2014

At a glance

  • Drugs Imatinib (Primary) ; Capecitabine; Dacarbazine
  • Indications Thyroid cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 16 Dec 2014 Status changed from completed to discontinued, as reported by ClinicalTrials.gov.
    • 21 Aug 2013 Status changed from discontinued to completed as reported by ClinicalTrials.gov.
    • 19 Aug 2013 Status changed from active, no longer recruiting to discontinued as reported by M.D. Anderson Cancer Center.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top